Hepatitis B virus X protein increases microRNA‑21 expression and accelerates the development of hepatoma via the phosphatase and tensin homolog/phosphoinositide 3‑kinase/protein kinase B signaling pathway

Hou,Zhouhua; Quan,Jun

doi:10.3892/mmr.2017.6363

Hepatitis B virus X protein increases microRNA‑21 expression and accelerates the development of hepatoma via the phosphatase and tensin homolog/phosphoinositide 3‑kinase/protein kinase B signaling pathway

Authors:
- Zhouhua Hou
- Jun Quan
View Affiliations

Affiliations: Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: March 23, 2017 https://doi.org/10.3892/mmr.2017.6363
Pages: 3285-3291

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatitis B virus (HBV) X protein (HBx) is a key regulatory protein that is involved in HBV infection, replication and carcinogenesis of hepatocellular carcinoma (HCC). The aim of the present study was to investigate the role of HBx in the progression and metastasis of liver cancer cells and to determine the underlying molecular mechanism of HBx in metastatic liver cancer cells. HBx protein expression was detected by western blot analysis, and microRNA (miR)‑21 levels were determined by reverse transcription‑quantitative polymerase chain reaction in the highly metastatic MHCC‑97H low metastatic MHCC‑97L and SMMC‑7721 liver cancer cell lines. The results demonstrated that the levels of HBx and miR‑21 were significantly increased in MHCC‑97H cells compared with MHCC‑97L and SMMC‑7721 cells. In addition, three pairs of small interfering (si)RNA specific to HBx were designed and synthesized to interfere with endogenous HBx in liver cancer cells, and the results demonstrated that knockdown HBx was associated with a corresponding decrease in miR‑21 expression. The MTT assay results demonstrated that cell viability significantly decreased in HBx‑siRNA cells compared with scramble siRNA‑transfected cells. In addition, transfection with an miR‑21 inhibitor inhibited MHCC‑97H cell proliferation. Furthermore, Transwell assay results revealed that downregulation of HBx and treatment with miR‑21 inhibitors contributed to the inhibition of MHCC‑97H cell invasion and metastasis. Western blot analysis demonstrated that miR‑21 inhibitors and HBx‑siRNA treatment led to the upregulation of phosphatase and tensin homolog (PTEN), and decreased levels of phosphoinositide 3‑kinase (PI3K), phosphorylated protein kinase B (Akt) and matrix metalloproteinase (MMP)‑2. The results of the present study indicated that HBx was positively associated with miR‑21 expression, and downregulation of miR‑21 and HBx suppressed MMP‑2 activity via the PTEN/PI3K/Akt signaling pathway. Therefore, HBx and miR‑21 may represent novel therapeutic targets for the treatment of HCC.

View Figures

View References

1	Waller LP, Deshpande V and Pyrsopoulos N: Hepatocellular carcinoma: A comprehensive review. World J Hepatol. 7:2648–2663. 2015. View Article : Google Scholar : PubMed/NCBI
2	Wogan GN, Kensler TW and Groopman JD: Present and future directions of translational research on aflatoxin and hepatocellular carcinoma. A review. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 29:249–257. 2012. View Article : Google Scholar : PubMed/NCBI
3	Lin HJ, Kao ST, Siao YM and Yeh CC: The Chinese medicine Sini-San inhibits HBx-induced migration and invasiveness of human hepatocellular carcinoma cells. BMC Complement Altern Med. 15:3482015. View Article : Google Scholar : PubMed/NCBI
4	Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL and Inoue M: Hepatitis B and C virus infection and hepatocellular carcinoma in China: A review of epidemiology and control measures. J Epidemiol. 21:401–416. 2011. View Article : Google Scholar : PubMed/NCBI
5	Xu Y, Li L, Xiang X, Wang H, Cai W, Xie J, Han Y, Bao S and Xie Q: Three common functional polymorphisms in microRNA encoding genes in the susceptibility to hepatocellular carcinoma: A systematic review and meta-analysis. Gene. 527:584–593. 2013. View Article : Google Scholar : PubMed/NCBI
6	Pollicino T and Saitta C: Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol. 20:5951–5961. 2014. View Article : Google Scholar : PubMed/NCBI
7	Ali A, Abdel-Hafiz H, Suhail M, Al-Mars A, Zakaria MK, Fatima K, Ahmad S, Azhar E, Chaudhary A and Qadri I: Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma. World J Gastroenterol. 20:10238–10248. 2014. View Article : Google Scholar : PubMed/NCBI
8	Lin L, Yin X, Hu X, Wang Q and Zheng L: The impact of hepatitis B virus×protein and microRNAs in hepatocellular carcinoma: A comprehensive analysis. Tumour Biol. 35:11695–11700. 2014. View Article : Google Scholar : PubMed/NCBI
9	Motavaf M, Safari S, Jourshari Saffari M and Alavian SM: Hepatitis B virus-induced hepatocellular carcinoma: The role of the virus×protein. Acta Virol. 57:389–396. 2013. View Article : Google Scholar : PubMed/NCBI
10	Kouwaki T, Okamoto T, Ito A, Sugiyama Y, Yamashita K, Suzuki T, Kusakabe S, Hirano J, Fukuhara T, Yamashita A, et al: Hepatocyte factor JMJD5 regulates hepatitis B virus replication through interaction with HBx. J Virol. 90:3530–3542. 2016. View Article : Google Scholar : PubMed/NCBI
11	Carmona S, Ely A, Crowther C, Moolla N, Salazar FH, Marion PL, Ferry N, Weinberg MS and Arbuthnot P: Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther. 13:411–421. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kim CM, Koike K, Saito I, Miyamura T and Jay G: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 351:317–320. 1991. View Article : Google Scholar : PubMed/NCBI
13	Feng H, Zhang J, Li X and Chen WN: HBX-mediated migration of HBV-replicating HepG2 cells: Insights on development of hepatocellular carcinoma. J Biomed Biotechnol. 2009:9302682009. View Article : Google Scholar : PubMed/NCBI
14	Gong J, He XX and Tian A: Emerging role of microRNA in hepatocellular carcinoma (Review). Oncol Lett. 9:1027–1033. 2015.PubMed/NCBI
15	Yin J, Bai Z, Song J, Yang Y, Wang J, Han W, Zhang J, Meng H, Ma X, Yang Y, et al: Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer. Chin J Cancer Res. 26:95–103. 2014.PubMed/NCBI
16	Liu Z, Wang J, Guo C and Fan X: MicroRNA-21 mediates epithelial-mesenchymal transition of human hepatocytes via PTEN/Akt pathway. Biomed Pharmacother. 69:24–28. 2015. View Article : Google Scholar : PubMed/NCBI
17	Zhang J, Xiao Z, Lai D, Sun J, He C, Chu Z, Ye H, Chen S and Wang J: MiR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer. Br J Cancer. 107:352–359. 2012. View Article : Google Scholar : PubMed/NCBI
18	Yang CH, Yue J, Pfeffer SR, Handorf CR and Pfeffer LM: MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem. 286:39172–39178. 2011. View Article : Google Scholar : PubMed/NCBI
19	Yang X, Wang X, Shen H, Deng R and Xue K: Combination of miR-21 with circulating tumor cells markers improve diagnostic specificity of metastatic breast cancer. Cell Biochem Biophys. 73:87–91. 2015. View Article : Google Scholar : PubMed/NCBI
20	Soria-Valles C, Gutiérrez-Fernández A, Guiu M, Mari B, Fueyo A, Gomis RR and López-Otín C: The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21. Oncogene. 33:3054–3063. 2014. View Article : Google Scholar : PubMed/NCBI
21	Lu X, Luo F, Liu Y, Zhang A, Li J, Wang B, Xu W, Shi L, Liu X, Lu L and Liu Q: The IL-6/STAT3 pathway via miR-21 is involved in the neoplastic and metastatic properties of arsenite-transformed human keratinocytes. Toxicol Lett. 237:191–199. 2015. View Article : Google Scholar : PubMed/NCBI
22	Ferraro A, Kontos CK, Boni T, Bantounas I, Siakouli D, Kosmidou V, Vlassi M, Spyridakis Y, Tsipras I, Zografos G and Pintzas A: Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGBeta4-PDCD4) as predictor of metastatic tumor potential. Epigenetics. 9:129–141. 2014. View Article : Google Scholar : PubMed/NCBI
23	Connolly EC, Van Doorslaer K, Rogler LE and Rogler CE: Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. Mol Cancer Res. 8:691–700. 2010. View Article : Google Scholar : PubMed/NCBI
24	Spinner DM: MTT growth assays in ovarian cancer. Methods Mol Med. 39:175–177. 2001.PubMed/NCBI
25	Sargent J, Elgie A, Taylor CG, Wilson J, Alton P and Hill JG: The identification of drug resistance in ovarian cancer and breast cancer: Application of the MTT assay. Contrib Gynecol Obstet. 19:64–75. 1994.PubMed/NCBI
26	Liu H, Huang X, Liu X, Xiao S, Zhang Y, Xiang T, Shen X, Wang G and Sheng B: MiR-21 promotes human nucleus pulposus cell proliferation through PTEN/AKT signaling. Int J Mol Sci. 15:4007–4018. 2014. View Article : Google Scholar : PubMed/NCBI
27	Koike K, Moriya K, Iino S, Yotsuyanagi H, Endo Y, Miyamura T and Kurokawa K: High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology. 19:810–819. 1994. View Article : Google Scholar : PubMed/NCBI
28	Benhenda S, Cougot D, Neuveut C and Buendia MA: Liver cell transformation in chronic HBV infection. Viruses. 1:630–646. 2009. View Article : Google Scholar : PubMed/NCBI
29	Blumberg BS: Primary and secondary prevention of liver cancer caused by HBV. Front Biosci (Schol Ed). 2:756–763. 2010. View Article : Google Scholar : PubMed/NCBI
30	Xiong B, Cheng Y, Ma L and Zhang C: MiR-21 regulates biological behavior through the PTEN/PI-3K/Akt signaling pathway in human colorectal cancer cells. Int J Oncol. 42:219–228. 2013.PubMed/NCBI
31	Xu J, Zhang W, Lv Q and Zhu D: Overexpression of miR-21 promotes the proliferation and migration of cervical cancer cells via the inhibition of PTEN. Oncol Rep. 33:3108–3116. 2015.PubMed/NCBI